hsvtk retrovirally-transduced donor t lymphocytes
Cell therapyexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2002 (NCT00423124)
Timeline
Indications
Mechanism of action
- T-lymphocytesTissue restoration
T-lymphocytes tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- hsvtk retrovirally-transduced donor t lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01204502 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2011 | University of London |
| NCT00914628 | Phase 3 | Feb 1, 2010 | MolMed S.p.A., Vita-Salute University of Milano. Italy |
| NCT01913106 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2007 | Methodist Cancer Center, Houston, Texas |
| NCT00423124 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2002 | MolMed S.p.A., Vita-Salute University of Milano. Italy |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MolMed S.p.A. | For profit | 2 | 2 | 2 | 2002 |
| Vita-Salute University of Milano. Italy | Academic/Hospital | 2 | 0 | 2 | 2002 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 1 | 1 | 1 | 2007 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2011 |
4 organizations
Page 1 / 1